Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose
(RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with
investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperabl...
Age: 18 years - 66+
Gender: All
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
This phase II trial compares capecitabine and temozolomide to lutetium Lu 177 dotatate for
the treatment of pancreatic neuroendocrine tumors that have spread to other parts of the body
(advanced) or are not able to be removed by surgery (unresectable). Chemotherapy ...
Age: 18 years - 66+
Gender: All
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide
LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who
experience progressive disease in the randomized part of the study may proceed to...
Age: 18 years - 66+
Gender: All
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants
with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET),
von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal St...
Age: 12 years - 66+
Gender: All
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
This phase III trial studies cabozantinib to see how well it works compared with placebo in
treating patients with neuroendocrine or carcinoid tumors that may have spread from where it
first started to nearby tissue, lymph nodes, or distant parts of the body (advanc...
Age: 18 years - 66+
Gender: All